RENEHAVIS

RENEHAVIS is a gel:
- Lubricating action.
- Improves mobility and joint function.
- It contains two components of low and high molecular weight sodium hyaluronate to support joint viscosupplementation.

- NAME: RENEHAVIS
- COMPOSITION: LMW (Low Molecular Weight Sodium Hyaluronate): 0.7 ml at 2.2% with a molecular weight of 1 x 10^6 Da.
HMW (High Molecular Weight Sodium Hyaluronate): 0.7 ml at 1.0% with a molecular weight of 2 x 10^6 Da.
- PRESENTATION: 1 x 0.7 ml.
- INDICATIONS: RENEHAVIS is an effective choice for the treatment of osteoarthritis due to its advanced composition of low and high molecular weight sodium hyaluronate.
- INJECTION DEPTH: Intra-articular injections.
- PROTOCOL: Treatment involves weekly administration into the synovial joint space, with a maximum of three injections, depending on the severity of joint degeneration. It is essential to disinfect the injection site before treatment and to proceed with aspiration of the effusion, if present, to avoid complications.
- DURATION: Up to 4 months.
- USE: Strict medical use.

- Syringe: 1 x 0.7 ml.

Knee.

LMW (Low Molecular Weight Sodium Hyaluronate): 0.7 ml at 2.2% with a molecular weight of 1 x 10^6 Da.
HMW (High Molecular Weight Sodium Hyaluronate): 0.7 ml at 1.0% with a molecular weight of 2 x 10^6 Da.

- The treatment should only be carried out by qualified medical personnel under sterile conditions.
- Do not reuse the syringe or attempt to sterilise the device again, as this may compromise safety.
- Follow national/local regulations for the safe disposal of needles and disposable materials.
- Consider that, as a biological product obtained by fermentation, there may be potential immunological risks to be clinically evaluated.
- Monitor any local adverse effects (pain, swelling, redness) and consult your doctor if they persist or worsen.
- Avoid use in combination with other untested intra-articular injectables with RENEHAVIS, unless medically indicated.
- Inform the patient about the possibility of transient reactions to administration and the need for follow-up with the doctor.

RENEHAVIS is contraindicated in the following cases:
- Do not inject if the injection site is infected or has skin diseases in the affected area.
- Do not use in patients with known hypersensitivity to sodium hyaluronate or other components of the product.
- Do not use in children.
- Avoid use if the sterile packaging is damaged or beyond the expiry date.
- Intra-articular injection is contraindicated in cases of septic arthropathy or severe systemic inflammatory conditions (general principle of caution for intra-articular injections of hyaluronic acid).

Treatment with RENEHAVIS is particularly indicated for patients with osteoarthritis, particularly in the medial compartment of the knee. The treatment helps restore synovial fluid viscosity and reduce inflammation, leading to a significant reduction in joint pain.